ClinicalTrials.gov
ClinicalTrials.gov Menu

An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02749071
Recruitment Status : Recruiting
First Posted : April 22, 2016
Last Update Posted : November 12, 2018
Sponsor:
Information provided by (Responsible Party):
EndoStim Inc.

Brief Summary:
The purpose of this investigation is to demonstrate the safety and effectiveness of Lower Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled study. After the implant procedure, subjects will be randomized to either the Treatment Group (immediate stimulation) or Control Group (delayed stimulation) for six months followed by an additional open-label phase in which all subjects will receive electrical stimulation. Subjects continue on stimulation treatment in an extended open-label follow-up phase through 5 years post-stimulation.

Condition or disease Intervention/treatment Phase
Gastroesophageal Reflux Disease (GERD) Reflux, Gastroesophageal Gastroesophageal Reflux Acid Reflux Procedure: Laparoscopic implantation surgery Device: EndoStim stimulation for first six months of study Device: EndoStim stimulation from Month 6 thru end of study Device: Sham EndoStim stimulation for first six months of study Not Applicable

Detailed Description:
The purpose of this investigation is to demonstrate the safety and effectiveness of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System in the treatment of subjects with gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled clinical investigation. After the implant procedure, subjects will be randomized to either the Treatment Group (immediate stimulation) or Control Group (delayed stimulation) for a 6-month, double-blind phase followed by an additional open-label treatment phase in which all subjects will receive electrical stimulation therapy for a total of 12 months. Subjects continue on stimulation treatment and an extended open-label follow-up phase includes an 18 month post-stimulation phone interview followed by annual visits through 5 years post-stimulation.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)
Study Start Date : May 2016
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arm Intervention/treatment
Sham Comparator: Control Group
This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
Procedure: Laparoscopic implantation surgery
Laparoscopic surgery to implant the pulse generator and bipolar lead.

Device: EndoStim stimulation from Month 6 thru end of study
Lower esophageal stimulation
Other Names:
  • EndoStim Implantable Pulse Generator (IPG)
  • lower esophageal stimulation

Device: Sham EndoStim stimulation for first six months of study
EndoStim device remains "off" (no stimulation delivered)

Experimental: Treatment Group
The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
Procedure: Laparoscopic implantation surgery
Laparoscopic surgery to implant the pulse generator and bipolar lead.

Device: EndoStim stimulation for first six months of study
Lower esophageal stimulation
Other Names:
  • EndoStim Implantable Pulse Generator (IPG)
  • lower esophageal stimulation

Device: EndoStim stimulation from Month 6 thru end of study
Lower esophageal stimulation
Other Names:
  • EndoStim Implantable Pulse Generator (IPG)
  • lower esophageal stimulation




Primary Outcome Measures :
  1. Rate of device and/or procedure-related serious adverse events [ Time Frame: 12 months ]
    Rate of occurrence of device and/or procedure-related serious adverse events after 12 months

  2. Percentage of subjects achieving pH success (pH<4 for mo more than 5.3% of time or at least 50% improvement in pH compared to baseline) [ Time Frame: Comparison of 6 months to baseline data ]
    Comparison between treatment and control group: percentage of subjects achieving pH success ((pH<4 for mo more than 5.3% of time or at least 50% improvement in pH compared to baseline)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to provide written informed consent
  2. Able and willing to comply with required study procedures and follow-up schedule
  3. 22 - 75 years of age at the time of informed consent
  4. Documented symptoms of gastroesophageal reflux disease (GERD) for longer than 6 months (regurgitation and/or heartburn which is defined as burning epigastric or substernal pain which responds to acid neutralization or suppression) which requires daily use of proton pump inhibitors (PPIs) or other anti-reflux drug therapy, who continue to have symptoms despite maximum medical therapy or are "intolerant" -severe side-effects (e.g. anaphylaxis or severe allergic reaction, recurrent C. difficile, severe hypomagnesaemia) to one PPI or mild/moderate side effect (e.g. nausea, vomiting, diarrhea or abdominal pain) to at least 2 PPIs of different chemical classes.
  5. Symptomatic improvement on PPI therapy demonstrated by a composite GERD-health-related quality of life (HRQL) score of ≥20 off PPI, and a ≥10 point improvement on PPI compared to the off PPI composite GERD-HRQL score. Patients who meet the definition above of PPI intolerant are not required to have ≥10 point improvement. The on-PPI score to satisfy this criterion will be the score from the GERD-HRQL assessment completed after resuming PPIs following the Baseline visit.
  6. Excessive lower esophageal acid exposure during pH monitoring (defined as distal esophageal pH < 4 for > 6.0% of the monitoring time) performed after at least 5 days off of PPIs and at least 2 days off of H2 blockers. At least 18 hour of esophageal pH recording will be considered adequate and inclusion will be based on the day (at least 18 hours of valid data) with the highest acid exposure percentage time.
  7. Esophagitis ≤ Grade B (Los Angeles (LA) classification) as measured by upper endoscopy off PPI and H2 blockers for 10-14 days
  8. Esophageal body contraction amplitude > 30 mmHg for > 30% of swallows and > 30% peristaltic contractions on HRM or ≥ 30% peristaltic contractions with DCI >450.
  9. Suitable surgical candidate able to undergo general anesthesia and laparoscopic surgery

Exclusion Criteria:

  1. Previous EndoStim LES System implant and/or implant attempt
  2. Previous surgery involving the gastroesophageal junction or the lead implant site, such as a Nissen fundoplication
  3. Previous endoscopic intervention for the treatment of GERD and/or Barrett's esophagus
  4. Hiatal hernia larger than 3 cm as determined by endoscopy
  5. History of gastroparesis
  6. Any non-GERD esophageal motility disorders that in the opinion of investigator precludes an anti-reflux procedure
  7. History of or known esophageal stricture or significant esophageal anatomic abnormalities (obstructive lesions, etc.)
  8. Barrett's esophagus or any grade of dysplasia
  9. Documented history of esophagitis Grade C or D (LA Classification)
  10. History of suspected or confirmed esophageal or gastric cancer
  11. Esophageal or gastric varices
  12. Symptoms of dysphagia more than once per week every week within the last 3 months
  13. Unable to tolerate withdrawal from H2 Blockers or PPI medications
  14. Suspected or known allergies to titanium, platinum, iridium, stainless steel, silicone, epoxy, or nylon
  15. Body mass index (BMI) > 35 kg/m2
  16. Any significant multisystem diseases
  17. Autoimmune or a connective tissue disorder (scleroderma, dermatomyositis, Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome, etc.) requiring therapy in the preceding 2 years
  18. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c > 9.5 in the previous 6 months or at screening/baseline
  19. Significant cardiac arrhythmia or ectopy or significant cardiovascular disease (i.e. unstable angina pectoris, hemodynamically significant valvular disease, severe congestive heart failure), or any cardiac therapeutic intervention within the last 6 months.
  20. Significant cerebrovascular event within the last 6 months
  21. Existing implanted electrical stimulator (pacemaker, implantable cardioverter defibrillator, deep brain stimulator (DBS), bone growth or pelvic floor stimulators, drug pumps, etc.)
  22. Female subject of child-bearing potential and is pregnant or nursing, or intends to become pregnant during the trial period, who is not using a reliable form of birth control
  23. Currently enrolled in other potentially confounding research
  24. Active infection as determined by the investigator
  25. History of any malignancy, other than basal cell carcinoma, in the last 2 years
  26. Life expectancy less than 3 years aa. Diagnosed major psychiatric disorder (bipolar, schizophrenia, etc.) bb. Any condition that, at the discretion of the investigator or sponsor, would interfere with accurate interpretation of the study endpoints or preclude participation in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02749071


Contacts
Contact: Debbie Uribe duribe@endostim.com

  Show 22 Study Locations
Sponsors and Collaborators
EndoStim Inc.
Investigators
Principal Investigator: Nicholas J Shaheen, MD, MPH University of North Carolina

Additional Information:
Responsible Party: EndoStim Inc.
ClinicalTrials.gov Identifier: NCT02749071     History of Changes
Other Study ID Numbers: CS-100
First Posted: April 22, 2016    Key Record Dates
Last Update Posted: November 12, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Gastroesophageal Reflux
Heartburn
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms